Polyphor

78 articles about Polyphor

• Polyphor presents new data at ECCMID from its lead antibiotic murepavadin and the new OMPTA POL7306

  4/17/2019

  Murepavadin to be more potent than standard of care anti-Pseudomonas antibiotics against multidrug and colistin resistant Pseudomonas aeruginosa isolates

• Polyphor announces enrollment of first patient in PRISM-UDR - the second, FDA agreed - Phase III clinical trial for murepavadin in patients with nosocomial pneumonia

  4/16/2019

  Murepavadin is the lead, pathogen specific, Phase III antibiotic belonging to the OMPTA family and potentially the first drug of a new class of antibiotics against Gram-negative bacteria in more than 50 years

• Polyphor shareholders approve all motions proposed by the Board of Directors at the Annual General Meeting

  4/12/2019

  Polyphor AG shareholders approved all motions put forward by the Board of Directors to the 22nd Annual General Meeting in Basel.

• Polyphor's antibiotic murepavadin receives US FDA Qualified Infectious Disease Product designation in four new indications

  4/12/2019

  Polyphor AG announced that the US Food and Drug Administration has designated murepavadin as a Qualified Infectious Disease Product in four additional indications; hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infection, bloodstream infection and complicated intra-abdominal infection.

• Polyphor appoints Gökhan Batur as Chief Commercial Officer

  4/9/2019

  Polyphor AG, a clinical stage, Swiss biopharmaceutical company focused on the discovery and development of antibiotics and immuno-oncology compounds announced the appointment of Gökhan Batur to the newly created position of Chief Commercial Officer.

• Polyphor to present data on murepavadin and its lead preclinical compound of its novel class of Gram-negative antibiotics at the 29th European Congress of Clinical Microbiology and Infectious Diseases

  4/5/2019

  Polyphor AG announced that 5 abstracts featuring data on its Outer Membrane Targeting Antibiotics, including both its lead product candidate murepavadin and its new medium-spectrum anti Gram-negative lead preclinical compound, will be presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases taking place in Amsterdam, Netherlands, from April 13 to16, 2019.

• Polyphor announces financial results for the full-year 2018

  3/15/2019

  Polyphor AG (SIX: POLN), a clinical stage, Swiss biopharmaceutical company focused on the discovery and development of antibiotics and immuno-oncology compounds announced its financial results for the full-year of 2018.

• Polyphor awarded grant from CARB-X of up to $5.6M to support development of novel antibiotic against multi-drug resistant Gram-negative pathogens

  2/4/2019

  CARB-X to fund the preclinical development and Phase I clinical trial of a novel OMPTA candidate.

• 

  Novo Nordisk Investment Fund Backs Companies Developing Therapies Combatting Antimicrobial Resist...

  1/21/2019

  Novo Nordisk’s investment arm, Novo Holdings, invested a little more than $20 million in four different companies over the course of 2018 through its REPAIR Impact Fund. That $165 million fund was established last year to support companies developing therapies to combat antimicrobial resistance.

• Polyphor announces positive results from the FDA Type B Guidance meeting on the planned Phase III study for balixafortide

  12/3/2018

  The proposed study is intended to support the global registration of balixafortide. Polyphor expects to enroll the first patient in the second quarter of 2019.

• Polyphor wins the Swiss Technology Award 2018

  11/21/2018

  Polyphor wins the most important technology prize for innovation and technology transfer in Switzerland in the category "Innovation Leader"

• CMDO Debra Barker to leave Polyphor; Frank Weber to assist in the transition

  10/25/2018

  Chief Medical and Development Officer Debra Barker has decided to leave Polyphor at year end for personal reasons and will support on a part time basis afterwards.

• Balixafortide combination with eribulin in metastatic breast cancer data presented at ESMO 2018 show consistent positive trend for all efficacy endpoints, including overall survival

  10/25/2018

  Polyphor presented new efficacy data on its immuno-oncology candidate, balixafortide, at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany.

• Polyphor to present new survival data for balixafortide at the 2018 European Society for Medical Oncology (ESMO) Congress

  10/18/2018

  Polyphor announced today that new survival data from clinical and preclinical trials of balixafortide will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany, October 19-23.

• Novo Holdings invests CHF 6.8 Million in Polyphor to accelerate the development of novel antibiotics against multi-drug resistant Gram-negative pathogens

  9/12/2018

  Novo REPAIR Impact Fund to invest up to CHF 11.5M in Polyphor's antibiotic OMPTA pipeline through a CHF 6.8M equity investment, as well as a potential additional CHF 4.7M investment against program-specific royalties

• Polyphor announces financial results for the first half 2018

  9/10/2018

  Polyphor AG today announced its financial results for the first half of 2018.

• Novo Holdings invested CHF 6.8 million in Polyphor to accelerate the development of new antibiotics against multidrug-resistant Gram-negative pathogens 

  9/10/2018

  Polyphor and Novo Holdings A / S announced today that got Polyphor CHF 6.8 million in new capital from Novo REPAIR Impact Fund to promote the development of novel antibiotics directed against proteins of the outer cell membrane.

• U.S. FDA grants Fast Track designation for Polyphor’s innovative immuno-oncology candidate balixafortide in combination with eribulin as third line therapy for metastatic breast cancer

  4/20/2018

  Polyphor announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its novel immuno-oncology candidate balixafortide (POL6326), in combination with eribulin, for the treatment of patients with HER2-negative metastatic breast cancer who previously received at least two chemotherapeutic regimens in the metastatic setting.

• Santhera Obtains Worldwide Exclusive License from Polyphor to Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis and Other Pulmonary Diseases

  2/15/2018

  Santhera will assume the global development, regulatory filings and commercialization of POL6014.

• Polyphor: Global No. 2 in the 2018 Antimicrobial Resistance Benchmark published by the Access to Medicine Foundation

  1/24/2018

  Polyphor has been selected by the Access to Medicine Foundation as one of the leading companies in the area of research and development against antimicrobial resistance, as published today in the first Antimicrobial Resistance Benchmark at the 2018 WEF Annual Meeting in Davos, Switzerland.